GeoVax to Present Next-Generation COVID-19 Vaccine and Cancer Treatment Advances at Major Biotech Conference

Atlanta-based biotechnology company GeoVax Labs (Nasdaq: GOVX) will present its strategic vision for 2025 at the upcoming BIO CEO & Investor Conference in New York, showcasing significant advances in their vaccine and immunotherapy programs. The presentation comes at a crucial time as the company expands its clinical trials for both COVID-19 vaccines and cancer treatments.

At the center of GeoVax's presentation is their lead clinical program, GEO-CM04S1, a next-generation COVID-19 vaccine that recently secured BARDA funding for a 10,000-participant Phase 2b clinical trial. This development marks a significant step forward in addressing ongoing challenges in COVID-19 protection, particularly for vulnerable populations.

The company's COVID-19 vaccine program is particularly noteworthy for its focus on immunocompromised patients, including those with hematologic cancers, who may not receive adequate protection from current vaccines. GEO-CM04S1 is currently undergoing three separate Phase 2 clinical trials, investigating its effectiveness as a primary vaccine for immunocompromised patients, a booster for chronic lymphocytic leukemia patients, and a more durable booster option for individuals who previously received mRNA vaccines.

Beyond COVID-19, GeoVax is making strides in oncology treatment with Gedeptin®, their gene-directed therapy for advanced head and neck cancers. Following the completion of a Phase 1/2 clinical trial, the company plans to initiate a Phase 2 trial in mid-2025, combining Gedeptin with an immune checkpoint inhibitor for treating first recurrent head and neck cancer.

The presentation of these developments at the BIO CEO & Investor Conference represents a critical juncture for both the company and the broader medical community. The advancement of these therapies could potentially address significant unmet medical needs, particularly for immunocompromised patients who remain vulnerable to COVID-19 despite existing vaccines, and for patients with advanced head and neck cancers who have limited treatment options.

The company's progress in these areas could have far-reaching implications for public health, especially in providing more effective protection against COVID-19 for vulnerable populations and advancing treatment options for aggressive cancers. These developments align with growing industry efforts to develop more targeted and effective therapeutic approaches for both infectious diseases and cancer treatment.